4.7 Article

Detecting earlier stages of amyloid deposition using PET in cognitively normal elderly adults

Journal

NEUROLOGY
Volume 94, Issue 14, Pages E1512-E1524

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0000000000009216

Keywords

-

Funding

  1. ADNI (NIH) [U01 AG024904]
  2. Department of Defense ADNI (Department of Defense) [W81XWH-12-2-0012]
  3. National Institute on Aging
  4. National Institute of Biomedical Imaging and Bioengineering
  5. AbbVie
  6. Alzheimer's Association
  7. Alzheimer's Drug Discovery Foundation
  8. Araclon Biotech
  9. BioClinica, Inc
  10. Biogen
  11. Bristol-Myers Squibb Co
  12. CereSpir, Inc
  13. Eisai Inc
  14. Elan Pharmaceuticals, Inc
  15. Eli Lilly and Co
  16. EuroImmun
  17. F. Hoffmann-La Roche Ltd
  18. Genentech, Inc
  19. Fujirebio
  20. GE Healthcare
  21. IXICO Ltd
  22. Janssen Alzheimer Immunotherapy Research & Development, LLC
  23. Johnson & Johnson Pharmaceutical Research & Development LLC
  24. Lumosity
  25. Lundbeck
  26. Merck Co, Inc
  27. Meso Scale Diagnostics, LLC
  28. NeuroRx Research
  29. Neurotrack Technologies
  30. Novartis Pharmaceuticals Corp
  31. Pfizer Inc
  32. Piramal Imaging
  33. Servier
  34. Takeda Pharmaceutical Co
  35. Transition Therapeutics
  36. Canadian Institutes of Health Research

Ask authors/readers for more resources

Objective To examine the feasibility of using cross-sectional PET to identify cognitive decliners among beta-amyloid (A beta)-negative cognitively normal (CN) elderly adults. Methods We determined the highest A beta-affected region by ranking baseline and accumulation rates of florbetapir-PET regions in 355 CN elderly adults using F-18-florbetapir-PET from the Alzheimer's Disease Neuroimaging Initiative (ADNI). The banks of the superior temporal sulcus (BANKSSTS) were found as the highest A beta-affected region, and A beta positivity in this region was defined as above the lowest boundary of BANKSSTS standardized uptake value ratio of A beta+ (ADNI-defined COMPOSITE region) CN individuals. The entire CN cohort was divided as follows: stage 0, BANKSSTS-COMPOSITE-; stage 1, BANKSSTS+COMPOSITE-; and stage 2, BANKSSTS+COMPOSITE+. Linear mixed-effect (LME) models investigated subsequent longitudinal cognitive change, and F-18-flortaucipir (FTP)-PET was measured 4.8 +/- 1.6 years later to track tau deposition. Results LME analysis revealed that individuals in stage 1 (n = 64) and stage 2 (n = 99) showed 2.5 (p < 0.05) and 4.8 (p < 0.001) times faster memory decline, respectively, than those in stage 0 (n = 191) over >4 years of mean follow-up. Compared to stage 0, both stage 1 (p < 0.05) and stage 2 (p < 0.001) predicted higher FTP in entorhinal cortex. Conclusions Nominally A beta- CN individuals with high A beta in BANKSSTS are at increased risk of cognitive decline, probably showing an earlier stage of A beta deposition. Our findings may help elucidate the association between brain A beta accumulation and cognition in A beta- CN cohorts. Classification of evidence This study provides Class II evidence that in elderly CN individuals those with high PET-identified superior temporal sulcus A beta burden have an increased risk of cognitive decline.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available